Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality

Expert Opinion on Pharmacotherapy
Andreas Pfützner, Thomas Forst

Abstract

Pioglitazone is an antidiabetic drug known to decrease peripheral, hepatic and vascular insulin resistance by the stimulation of PPARgamma. In clinical trials, pioglitazone as monotherapy or in combination with other oral antidiabetic drugs or insulin has demonstrated to effectively improve blood glucose levels, long-term glucose control and the lipid profile. The vascular effects of pioglitazone include improvement of endothelial function and microcirculation, reduction of blood pressure and inflammatory surrogate markers of atherosclerosis, and a reduction of a composite measure of macrovascular events (death, stroke and myocardial infarctions). The drug is well tolerated and has an acceptable side effect profile. Because of its additional microvascular and macrovascular effects, pioglitazone is an attractive and effective treatment option for the management of Type 2 diabetes mellitus.

References

Aug 14, 1999·Diabetologia·J Auwerx
Apr 18, 2000·Lancet·K Schoonjans, J Auwerx
Jun 6, 2000·Nature·S KerstenW Wahli
Sep 13, 2000·Drugs·P S Gillies, C J Dunn
May 1, 2001·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·M B DebrilJ Auwerx
May 22, 2001·Journal of Clinical Pharmacology·T PrueksaritanontJ D Rogers
Jun 26, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·C G Gegick, M D Altheimer
Jul 10, 2001·The Journal of Clinical Endocrinology and Metabolism·H KoshiyamaY Nakamura
Aug 9, 2001·Coronary Artery Disease·S RosenblattUNKNOWN Pioglitazone 026 Study Group
Mar 20, 2002·Annals of Internal Medicine·Louis D MayDavid E Rubin
Apr 12, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·S NagasakaS Ishibashi
Jun 7, 2002·The Journal of Clinical Endocrinology and Metabolism·Yoshinori MiyazakiRalph A DeFronzo
Jul 3, 2002·Drugs·Fabrice M A C MartensTon J Rabelink
Jul 20, 2002·Pharmacotherapy·Nancee V Niemeyer, Laurel M Janney
Nov 20, 2002·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·W A ScherbaumUNKNOWN German Pioglitazone Study Group
Dec 6, 2002·The Journal of Clinical Endocrinology and Metabolism·S FüllertT Konrad
Jun 27, 2003·Drugs·Michaela Diamant, Robert J Heine
Sep 10, 2003·Best Practice & Research. Clinical Endocrinology & Metabolism·Hannele Yki-Järvinen
Jan 24, 2004·Diabetes Research and Clinical Practice·Lois JovanovicPaula M Hale
Mar 6, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Jagdip S SidhuJuan Carlos Kaski
Jul 22, 2004·The Annals of Pharmacotherapy·Todd R MarcySteve M Blevins
Jul 24, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·M H TanUNKNOWN GLAC Study Group
Aug 24, 2004·BMJ : British Medical Journal·Ed Farley-HillsM Martin
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Sep 18, 2004·Metabolism: Clinical and Experimental·Tsukasa NakamuraHikaru Koide

❮ Previous
Next ❯

Citations

May 14, 2008·Diabetes Technology & Therapeutics·Efstrathios KaragiannisThomas Schöndorf
Apr 22, 2010·Vascular Health and Risk Management·Toshikazu Yamanouchi
Aug 19, 2007·Expert Opinion on Pharmacotherapy·Andreas PfütznerThomas Forst
Oct 19, 2006·The Journal of Surgical Research·Hayder H Al-AzzawiHenry A Pitt
Sep 16, 2014·Epilepsy Research·Prasarn ManitpisitkulDonald Heald
Oct 30, 2008·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Thomas ForstMarkolf Hanefeld
Mar 3, 2007·The Journal of Pharmacy and Pharmacology·Ali Murat IratNuray Ari
May 1, 2007·Expert Review of Endocrinology & Metabolism·Thomas Forst, Andreas Pfützner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.